ZA200309710B - Pharmaceutical formulation containing an LTB4 antagonist. - Google Patents
Pharmaceutical formulation containing an LTB4 antagonist. Download PDFInfo
- Publication number
- ZA200309710B ZA200309710B ZA200309710A ZA200309710A ZA200309710B ZA 200309710 B ZA200309710 B ZA 200309710B ZA 200309710 A ZA200309710 A ZA 200309710A ZA 200309710 A ZA200309710 A ZA 200309710A ZA 200309710 B ZA200309710 B ZA 200309710B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- tablet according
- denotes
- formula
- tablet
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 239000005557 antagonist Substances 0.000 title claims description 9
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 21
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 20
- 239000008101 lactose Substances 0.000 claims description 20
- 239000013543 active substance Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 14
- 239000000594 mannitol Substances 0.000 claims description 14
- 235000010355 mannitol Nutrition 0.000 claims description 14
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 13
- 239000000080 wetting agent Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 238000004040 coloring Methods 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 239000002706 dry binder Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229920002678 cellulose Chemical class 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920003124 powdered cellulose Polymers 0.000 claims description 3
- 235000019814 powdered cellulose Nutrition 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000000391 vinyl group Chemical class [H]C([*])=C([H])[H] 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960001375 lactose Drugs 0.000 description 16
- 229920001531 copovidone Polymers 0.000 description 13
- 229960000913 crospovidone Drugs 0.000 description 12
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 12
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 11
- 239000008187 granular material Substances 0.000 description 9
- 230000006835 compression Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229940125890 compound Ia Drugs 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- -1 (dimethyl)-siloxane chains Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920003105 Methocel™ A15 LV Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 2
- 229960003988 indigo carmine Drugs 0.000 description 2
- 235000012738 indigotine Nutrition 0.000 description 2
- 239000004179 indigotine Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 101100398835 Caenorhabditis elegans leo-1 gene Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000001117 sulphuric acid Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Description
I, : «+. 2003/9710 ® Case 1/1228-FF BOEHRINGER INGELHEIM PHARMA KG 78502f1t.206
Pharmaceutical formulation containing an LTB, antagonist
The invention relates to a new pharmaceutical formulation containing an LTB, antagonist which contains a benzamidine group, processes for the preparation thereof as well as the use thereof as a pharmaceutical composition.
LTB, antagonists which contain a benzamidine group are compounds with pharmacologically valuable properties. LTB4 antagonists may provide great therapeutic benefit, for example, in the treatment of treat arthritis, asthma, chronic obstructive lung diseases, psoriasis, ulcerative colitis, Alzheimer’s disease, shock, reperfusion damage/ischaemia, cystic fibrosis, atherosclerosis and multiple sclerosis.
Such compounds are known e.g. from International Patent Applications WO 93/16036, WO 94/11341, WO 96/02497, WO 97/21670, WO 98/11062, WO 98/11119, WO 01/25186 and
PCT/EP01/00262 .
These compounds have the chemical structure of formula I:
R, A NR,
R; TH (I)
NH,
R; wherein
A denotes a group of formula -0-CmHom-O-(PHE),- ( II ) wherein m is an integer from 2 to 6, preferably 2 to 5, nisOorl,
v ® “2 -
PHE denotes a 1,4-phenylene group optionally substituted by one or two
C1-Ce alkyl groups, preferably a 1,4-phenylene group substituted by a C,-
C4 alkyl group in the ortho position linked to the oxygen; or
A denotes a group of formula
CH,-O0— —oanf J” (mr) preferably of formula —O-CH, CH,-O0—
Tr (101A)
Ry denotes H, OH, CN, COR, or CHO, preferably H or COOR yg;
Rs denotes H, Br, Cl, F, CF;, CHF,, OH, HSO3-0O, C;-Cs-alkyl, C;-C¢-alkoxy, Cs-
Cy-cycloalkyl, CONRgRy, aryl, O-aryl, CHs-aryl, CRsRs-aryl, or C(CHa),-R, preferably OH, HSOs-O, CONRgRg or CRsRs-aryl,
Rs denotes H, C;-Cs -alkyl, C; -Cs-alkoxy, OH, Cl or F, preferably H or C; —Cs- alkoxy,
Rs denotes H or C;-Cs-alkyl, preferably H;
Rs denotes C;-Cs-alkyl, CFs, CH,OH, COOH or COO(C;-Cs-alkyl), preferably
Ci-Cs-alkyl, particularly methyl;
Rs denotes H, C;-Cs-alkyl or CFs, preferably Cy-Cy-alkyl, particularly methyl,
R; denotes CH,OH, COOH, COO(C;-C4-alkyl), CONR3sRy or CH,NR;3Ry;
Rg denotes H, C;-Cs-alkyl, phenyl, phenyl-(C,-Cs-alkyl), COR 15, COORyo, CHO,
CONH;, CONHR 0, SO2~(C;-Cs-alkyl), SOz-phenyl, while the phenyl group may be mono- or disubstituted by Cl, F, CFs, Ci-Cs-alkyl, OH and/or C;-C,- alkoxy, and preferably denotes C;-Cs-alkyl, particularly isopropyl,
Ro denotes H or C;-Cs-alkyl, preferably H or C;-Cy-alkyl, particularly isopropyl; or
Rs and Ry taken together represent a Cy-Cg-alkylene group;
Rio denotes C;-Cs-alkyl, Cs-C;-cycloalkyl, aryl, heteroaryl, aralkyl or heteroaryl- (C:-Cs-alkyl), preferably C-Cs-alkyl,
v ® -3. while the aryl groups mentioned in groups R; and Ryo denote phenyl or naphthyl, the heteroaryl groups denote pyrrole, pyrazole, imidazole, furanyl, thienyl, pyridine or pyrimidine and may each be mono- or polysubstituted by Cl, F, CFs, C;-C,-alkyl, OH,
HS03-0 or C;-Cy-alkoxy, preferably by OH or HSO3-O-.
The aim of the present invention is to provide an orally administered pharmaceutical formulation which releases an active substance of formula I relatively fast and completely and thus leads to greater bioavailability of this active substance. A further object of the present invention is to prepare a formulation which is characterised by ease of handling during the preparation process and thus can be produced industrially in a reproducible manner while maintaining a constant high quality.
The objective stated above are solved by the formulation described in detail hereinafter.
The present invention relates to a tablet containing a compound of formula I which contains a compound of formula I, the pharmacologically acceptable acid addition salts thereof and glucuronides, and at least one pharmacologically acceptable excipient, the tablet containing at least one wetting agent.
A further aim is the use of a tablet according to one of claims 1 to 14 for preparing a pharmaceutical composition with increased bioavailability for the treatment or prevention of diseases in which LTB, antagonists can be used therapeutically or preventively.
The active substance of formula I may be present in the formulation according to the invention in the form of a physiologically acceptable acid addition salt. By physiologically acceptable acid addition salts are meant, according to the invention, pharmaceutically acceptable salts which are selected from the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid and maleic acid. Mixtures of the above acids may also be used to prepare the salts. According to the invention, the preferred salts of formula are selected from among the hydrochloride, hydrobromide, sulphate, phosphate, fumarate and methanesulphonate. The salts selected from among the hydrochloride, hydrobromide and fumarate are particularly preferred. The active substance may optionally be in the form of a hydrate. Preferably, according to the invention, the compound of formula I is added to the tablet in the form of the free base and in the anhydrous form.
Particularly preferred compounds of formula I are the compounds of formulae IA, IB and IC, particularly IA:
H,C &
HO . 0 (IA)
OH
O
OL C
H,C
NH,
NH
(IB) 0
SENS Ge i-C,H, 0 NH,
CH, NH
The compounds of formula I wherein R; is different from hydrogen are generally prodrugs which are converted in vivo into the corresponding compounds of formula I wherein R; is hydrogen.
For example, from the compound IA is formed in vivo the compound of formula IA1:
Hc Hs
BORO POV
Tw
NH
(1A1) wherein X denotes OH, HSOs3-O or a carbohydrate group of formula CsH;;05-O-.
Preferably, the active substance is used in crystalline, unground form or in ground form, particularly in jet-ground form, wherein the particle size distribution is within the following limits: Dig <3 um, Dsg 3 to 8 um, Dgp < 8 to 30 um. The abovementioned numerical data for
Dy, Dso and Dg in um (microns) are the particle size ranges within which a throughput total of 10 vol.%, 50 vol.% or 90 vol.% of the particles measured (cumulative volume distribution) is achieved. These values were determined by the laser diffractometry method, specifically, in the present instance, using a so-called dry dispersion under a dispersion pressure of 2 bar and with a focal length f= 500 mm, e.g. using a Sympatec/RODOS apparatus. This methodology is known in the prior art.
Where reference is made to salts of the compounds of formula I within the scope of the present invention, this is indicated by the symbol I‘. Explicit references to the free base of formula I, on the other hand, are indicated by the use of the symbol L
In relation to the total mass of the tablets according to the invention the compound of formula
I, particularly IA is present in an amount of up to 0.2 to 80 wt.%, preferably 0.7 to 40 wt.%, more preferably about 5 to 38 wt.%. Particularly preferably, the content of the free base of is between 6 and 36 wt.% based on the total mass of the tablet.
. ® -6 -
The term “wetting agent” as used hereinbefore and hereinafter denotes an excipient which lowers the surface tension of water or other liquids so that they can penetrate into the surfaces of the tablets according to the invention and soak through them, displacing the air, thereby wetting them. The substances used as wetting agents are usually interface-active surfactants.
These surfactants are amphiphilic (bifunctional) compounds with at least one hydrophobic and one hydrophilic part of the molecule. The hydrophobic group is usually a hydrocarbon chain, if possible a straight chain, with eight to 22 carbon atoms. Particular surfactants may also have (dimethyl)-siloxane chains or perfluorinated hydrocarbon chains as the hydrophobic part of the molecule. The hydrophilic group is either a negatively or positively charged (hydratable) or a neutral polar head group. Of the surfactants, anionic surfactants, particularly the long-chain alkylsulphates, especially sodium laurylsulphate and alkylbenzenesulphonates are preferred.
According to the invention, the weight ratio between the components, namely wetting agent and active substance I , contained in the tablet is in a range from about 1:200 to about 1:5, preferably between about 1:150 and about 1:10.
The pharmaceutical formulation according to the invention contains in addition to the active substance at least one excipient as a filler/dry binder.
Within the scope of the present invention carbohydrates such as lactose or mannose, particularly finely divided lactose or sugar alcohols such as mannitol, sorbitol or xylitol, particularly mannitol, are of particular importance as excipients. These excipients have proved particularly advantageous in the formulation according to the invention. In a preferred aspect, therefore, the present invention relates to a tablet containing at least one compound of formula
I, which contains, in addition to the active substance and the wetting agent, lactose, particularly finely divided lactose, more preferably lactose monohydrate or mannitol as excipient.
According to the invention the weight ratio between the components lactose or mannitol to active substance I contained in the tablet is in a range from about 20:1 to about 1:4.
Preferably, the ratio of lactose to 1 is in a range from about 1.8:1 to about 1:1.2, more
> ® -7 - preferably in a range from about 1.4:1 to 1.6:1. Preferably, the proportion by weight of lactose based on the total mass of the tablet according to the invention is in a range of about 1 - 70 wt.%, preferably about 2 - 60 wt. %.
Preferably, the ratio of mannitol to Lis in a range of about 20:1 to about 1:2, more preferably in arange of about 15:1 to 3:1. Preferably the proportion by weight of mannitol based on the total mass of the tablet according to the invention is in a range of about 20 - 90 wt.%, preferably between about 40 - 75 wt.%.
The tablet according to the invention may also contain, in addition to lactose, wetting agent and active substance, further excipients or fillers. According to the invention, it is preferable to use compounds capable of acting as binders.
The term “binder” used hereinbefore and hereinafter denotes excipients which are suitable for binding other components to one another. Preferred binders according to the invention are selected from among: powdered cellulose, microcrystalline cellulose, sorbitol, starch, polyvinylpyrrolidone (povidone), copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), cellulose derivatives, particularly methylhydroxypropylcellulose, e.g. Methocel A 15 LV, and mixtures of these compounds. The preferred binders are powdered cellulose, particularly microcrystalline cellulose and/or copovidone. Most preferred is a mixture of microcrystalline cellulose and a copolymer of vinylpyrrolidone and vinyl acetate, namely copovidone VA 64, the ratio of vinylpyrrolidone and vinyl acetate being about 3:2 (m/m). As a rule the tablet according to the invention has a weight ratio of microcrystalline cellulose to copovidone VA 64 of 20:1 to 1:1, preferably 15:1 to 2:1, particularly about 10:1 to 3:1. Thanks to this particularly preferred binder combination of microcrystalline cellulose and copovidone, tablets are obtained having a high bioavailability of the compounds of formula I.
If one of the abovementioned binders is added to the formulation according to the invention, the weight ratio of lactose to binder is preferably about 10:1 to about 1:2, preferably about 5:1 to about 1:1, more preferably about 4.5:1 to 3.5:2.
- @ . _g.
If one of the abovementioned binders is added to the formulation according to the invention, the weight ratio of mannitol to binder is preferably about 10:1 to about 1:2, preferably about 5:1 to about 1:1, more preferably about 3.5:1 to 3.0: 1.
The tablet according to the invention may also contain disintegrants in addition to the abovementioned ingredients. Within the scope of the present invention these disintegrants may optionally also be known as breakdown agents. These are preferably selected, according to the invention, from among sodium starch glycolate, crosslinked polyvinylpyrrolidone (crospovidone), croscarmellose sodium salt (sodium salt of cellulose carboxymethyl ether, crosslinked), sodium-carboxymethylcellulose (?), dried maize starch and mixtures thereof.
Within the scope of the present invention it is particularly preferred to use sodium starch glycolate, crospovidone and, preferably, the sodium salt of crospovidone or croscarmellose.
If the abovementioned disintegrants are used, the amount by weight, based on the total mass of the tablet according to the invention, is preferably in a range of about 0.5 - 10 wt.%, more preferably about 1.5 —7.5 wt. %.
The tablet according to the invention may also contain flow agents or flow regulators and also lubricants, as additional ingredients. These include, within the scope of the present invention, for example, silicon dioxide, talc, stearic acid, sodium stearylfumarate, magnesium stearate and glycerol tribehenate. According to the invention magnesium stearate is preferably used. If the abovementioned flow agents or flow regulators or lubricants are used, the amount by weight thereof, based on the total mass of the tablet according to the invention, is preferably in arrange of about 0.1 - 10 wt.%, preferably about 0.5 — 5 wt.%, more preferably between 0.6 and 1.5 wt.%.
In addition, the tablet according to the invention may contain one or more synthetic or natural, pharmaceutically acceptable dyes or colourings, preferably indigo carmine. If the abovementioned colourings are used the amount by weight thereof based on the total mass of the tablet according to the invention is 0.01 to 0.5 wt.%.
Particularly preferred is a tablet consisting essentially of the following ingredients: e a compound of formula I, preferably 5 wt.% to 50 wt.%, particularly 6 wt.% to 45 wt.% of a compound of formula IA;
@ e microcrystalline cellulose, preferably 0., wt.% to 25 wt.%, particularly 5 wt.% to 20 wt.% microcrystalline cellulose; ¢ lactose, preferably 15 wt.% to 80 wt.%, particularly 20 wt.% to 75 wt.% lactose; or mannitol, preferably 20 wt.% to 90 wt.%, particularly 40 wt.% to 75 wt.% mannitol; e optionally a copolymer of vinylpyrrolidone and vinyl acetate, preferably 0.2 wt.% to 5 wt.%, particularly 0.5 wt.% to 2.5 wt.% of copovidone V64, e sodium lauryl sulphate, preferably 0.01 wt.% to 10 wt.%, particularly 0.06 wt.% to 7 wt.% of sodium lauryl! sulphate; e crosslinked polyvinylpyrrolidone, preferably 0.4 wt.% to 8 wt.%, particularly 0.8 wt.% to 6 wt.%; or crosslinked cellulose carboxymethylether sodium salt, particularly croscarmellose sodium salt; e magnesium stearate, preferably 0.1 wt.% to 5 wt.%, particularly 0.5 wt.% to 1.5 wt.% of magnesium stearate; and e optionally a colouring.
The tablet according to the invention may be prepared by directly mixing and compressing the ingredients or by granulation and compression. To prepare the tablet according to the invention the following procedure may be used, for example.
The active substance of formula I, the wetting agent and optionally a copolymer of vinylpyrrolidone and vinyl acetate as binder are dissolved or suspended in water, granulated with the excipients, particularly lactose monohydrate and optionally microcrystalline cellulose as an additional binder, screened and then dried. The product obtained is optionally mixed with the flow agent, particularly magnesium stearate and screened. Then a disintegrant, particularly crospovidone, is optionally added. The mixture of active substance and excipient thus obtained is then compressed in a suitable tablet press to form the tablets according to the invention.
The compression forces which are needed to produce tablets of suitable breaking resistance and hence with the required breakdown times are dependent on the shapes and sizes of the punching tools used. Compression forces in the range from 2 - 20 kN are preferred. Higher
@ compression forces may lead to tablets with a delayed released of active substance. Lower compression forces may produce mechanically unstable tablets. The tablet cores may have different shapes; the preferred shapes are round biplanar or biconvex and oval or oblong forms.
The Examples that follow serve to illustrate some formulations according to the invention.
They are intended solely as possible procedures described by way of example, without restricting the invention to their content.
@
Example 1: (01) compound IA, jet-ground | 7500 [ (02) microcrystalline cellulose | 2250 [ 09) tase LC (04) copovidone VA 64 BEE (05) sodium laurylsulphate BEE 09) wa ww (07) crospovidone BE (08) magnesium stearate
Preparation (variant 1) 1 batch = 2992.5 g = 13,300 tablets 1. Premix
In a suitable intensive mixer, e.g. Diosna P10, 997.500 g of jet-ground compound of formula
IA, 299.250 g of microcrystalline cellulose and 1523.648 g of lactose monohydrate are mixed for 3 minutes. 2. Granulating liquid 518,700 g of water are placed in a suitable container. 49,875 g of copovidone VA 64 are slowly stirred in using a suitable stirrer. After the povidone VA 64 has dissolved, 9.975 g of sodium laurylsulphate are stirred in. 3. Granules
After the addition of the granulating liquid 2. using a liquid funnel the premix 1. is mixed wet and granulated in an intensive mixer.
Moist screening
The moist granules thus produced are moist screened with a suitable screening machine, e.g.
Erweka AR401, with a mesh size of 1.6 mm .
i -12 -
Drying
In a suitable drying cupboard, e.g. a WTB Binder, the granules are dried for 10 hours in a layer thickness of about 1 cm at a temperature of 50°C.
Dry screening
Using a suitable screening machine, e.g. Erweka AR401, the dried granules are dry-screened with a mesh size of 0.8 mm. 4. Final mixture
In a suitable container with a suitable mixer, e.g. an Rm 100 gyrowheel mixer, 2880.248 g of the screened granules 3. are added to 89.775 g of crospovidone at 30 rpm and the components are homogeneously mixed for 10 minutes. Then 22.477 g of magnesium stearate are added to the mixture and it is homogeneously mixed for 5 minutes. 5. Tablet making
In a suitable tablet press, e.g. EK 0 (pressing tool: 9 mm with radius of convexity of 13.5 mm and faceted), 2992.500 g of the final mixture 4. are compressed at a compression speed of 25 tablets./min. to produce tablets weighing 225 mg each.
The tablets thus obtained have the following properties: weight 225mg diameter 9 mm height about 3.6 mm breaking strength 100 N (n= 10 hrs) disintegration < 8 minutes friability - abrasion <0.5%
- @
Example 2: (01) compound IA, jet-ground 75000 (02) microcrystalline cellulose 2500 (03) fine lactose tase |] (04) copovidone VA 64 HEE (05) sodium laurylsulphate | nse 09 wt I CL (07) crospovidone 6150 (08) magnesium stearate La
The tablets are prepared analogously to Example 1. The tablets obtained have comparable physical data.
Example 3: (01) compound IA, jet-ground | 75000 1] (02) microcrystalline cellulose | esaso 1 (03) fine lactose 82% 1] (04) Methocel A 15 LV BEX (05) sodium laurylsulphate HEE 09 I (07) crospovidone emo To] (08) magnesium stearate 2250
The tablets are prepared analogously to Example 1. The tablets obtained have comparable physical data, but lower hardness and a slower rate of dissolution.
- @
Example 4: nen (01) compound IB, jet-ground | 75000 [ (02) microcrystalline cellulose 2250 [ (03) fine lactose 14s [ (04) copovidone VA 64 HEE (05) sodium laurylsulphate oso 09 va I (07) crospovidone 6150 |] (08) magnesium stearate Leo 1
The tablets are prepared analogously to Example 1. The tablets obtained have comparable physical data.
Example S: (01) compound IC, jet-ground | 75000 1] (02) microcrystalline cellulose 2250 |] (03) fine lactose | lase [ (04) copovidone VA 64 EEE (05) sodium laurylsulphate om fp] 09 vic |r (07) crospovidone 6750 |] (08) magnesium stearate Leo
The tablets are prepared analogously to Example 1. The tablets obtained have comparable physical data.
- @
Example 6 (01) compound IA, jet-ground | 7000 (02) microcrystalline cellulose | nso 52) tacos EL (04) copovidone VA 64 HEE (05) sodium laurylsulphate ome 09) var I (07) crospovidone 610 (08) magnesium stearate Leo
Preparation (variant 2)
I. Premix
In a suitable one-pot granulator, e.g. Zanchetta Roto P 50, 4.6500 kg of jet-ground compound of formula IA, 1.3950 kg of microcrystalline cellulose, 7.1028 kg lactose and 0.4185 kg crospovidone are mixed for 3 minutes. 2. Granulating liquid 2.1762 kg of water (corresponding to 90% of the quantity in process 1) are placed in a suitable container. 0.2325 kg of copovidone VA 64 are slowly stirred in using a suitable stirrer. After the povidone VA 64 has dissolved, 0.0465 kg of sodium laurylsulphate are stirred in. 3. Granules
After the addition of the granulating liquid the premix 1. is mixed wet and granulated in a one-pot granulator.
Drying
The granules are dried for 50 minutes in a one-pot granulator at a temperature of 49°C.
. @
Dry screening
Using a suitable screening machine, e.g. Comil 197 S, the dried granules are dry-screened with a mesh size of RS 2007. 4. Final mixture
In a suitable gravity mixer, e.g. Servolift Kubus 60 1, 13,8453 kg of the screened granules 3. and 0.1047 kg magnesium stearate are homogeneously mixed at 10 rpm for 5 minutes. 5. Tablet making
In a suitable tablet press, e.g. Fette P 1200 (pressing tool: 9 mm with radius of convexity of 13.5 mm and faceted), 13.9500 kg of the final mixture 4. are compressed at a compression speed of 100,000 tablets /hr to produce tablets weighing 225 mg each.
Example 7
Ingredients (01) compound IA, jet-ground (02) microcrystalline cellulose (03) mannitol (04) croscarmellose sodium (05) sodium laurylsulphate (06) indigo carmine (11-14 %) (07) magnesium stearate
The direct compression comprises producing a premix of ingredients (01), (05), (06) and some of (03) with a Diosna® intensive mixer. The premix is screened and mixed with ingredients (02), (04) and the remainder of (03) in a Turbula® gravity mixer. After the mixture has been screened again, ingredient (07) is added. A corresponding flow diagram is shown in Figure 2.
Biconvex tablets 6 mm thick with rounded edges, containing 5 mg of the compound of formula IA with a total weight of 75 mg are compressed
Example 8
The tablets of Examples 1 to 3 according to the invention are administered to healthy male subjects by oral route in a single dose. The plasma concentration of the active substance is determined from time to time. The mean data thus obtained are shown graphically in Figure 1.
In Fig. 1 the blood plasma concentration in ng/ml of the glycoside of the compound of formula IA1 produced in vivo from the compound of formula IA is plotted against the time in hours. According to this, the highest concentration of active substance in the plasma is obtained with the tablet according to Example 1.
The symbols used in Fig. 1 have the following meanings: —— tablet of Example 1 —A— tablet of Example 2 —0— tablet of Example 3
Claims (19)
1. Pharmaceutical formulation in the form of a tablet containing an LTB, antagonist of formula I, R, A NR, NH R; 2 wherein A denotes a group of formula -0-CpHzm-O-(PHE),- (mm) wherein m is an integer from 2 to 6, nis 0 or 1, PHE denotes a 1,4-phenylene group optionally substituted by one or two C1-Cs alkyl groups; or A denotes a group of formula CH,-0— adl (1) R; denotes H, OH, CN, COR}, or CHO; R; denotes H, Br, CI, F, CFs, CHF,, OH, HS0;-0O, C;-Cs-alkyl, C;-Cs-alkoxy, Cs- Cs-cycloalkyl, CONR3Ry, aryl, O-aryl, CH;-aryl, CRsR¢-aryl, or C(CHz),-Ry, Rj; denotes H, C,-Cs -alkyl, C; -C¢-alkoxy, OH, Cl or F, Ry denotes H or C,;-Cs-alkyl; Rs denotes C;-Cy-alkyl, CFs, CH,OH, COOH or COO(C,;-C4-alkyl), Rs denotes H, C,-C;s-alkyl or CFs; R; denotes CH,OH, COOH, COO(C,-C;4-alkyl), CONRgRy or CH,NRgRo; Rs denotes H, C;-Cs-alkyl, phenyl, phenyl-(C;-C¢-alkyl), COR 9, COOR yo, CHO, CONHz, CONHR 19, SO2-(C1-Ce-alkyl), SO,-phenyl, while the phenyl group may be mono- or disubstituted by Cl, F, CFs, C;-Cy4-alkyl, OH and/or C;-Cs- alkoxy, Ro denotes H or C;-Cs-alkyl; or Rg and Ry taken together represent a C4-Cs-alkylene group; Rio denotes C;-Cs-alkyl, Cs-Cr-cycloalkyl, aryl, heteroaryl, aralkyl or heteroaryl- (Ci-Cs-alkyl), while the aryl groups mentioned in groups Rz and Ryo denote phenyl or naphthyl, the heteroaryl groups denote pyrrole, pyrazole, imidazole, furanyl, thienyl, pyridine or pyrimidine and may each be mono- or polysubstituted by Cl, F, CFs, C;-C4-alkyl, OH, HSO03-0 or Ci-Cy-alkoxy, as well as the pharmacologically acceptable acid addition salts and glycosides and 0- sulphates thereof; and at least one pharmacologically acceptable excipient, characterised in that the tablet contains at least one wetting agent.
2. Tablet according to claim 1, characterised in that the LTB, antagonist is a compound selected from among formulae IA, IB and IC: H,C oH HO o je NO 0) (1A) OH H,C NH, NH
(IB) 0 1-C,H Oo ~~ LX i-C,H NH 3777 0 2 CH, NH dC)
3. Tablet according to one of claims 1 or 2, characterised in that the wetting agent is an anionic surface-active substance.
4. Tablet according to one of claims 1 to 3, characterised in that the wetting agent is sodium laurylsulphate.
5. Tablet according to one of claims 1 to 4, characterised in that it contains lactose or mannitol as excipient.
6. Tablet according to one of claims 1 to 5, characterised in that it additionally contains at least one dry binder, at least one lubricant, at least one disintegrant and/or at least one separating agent and optionally a colouring.
7. Tablet according to claim 6, characterised in that the dry binder is selected from among powdered cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives, cellulose derivatives and mixtures of these compounds. :
8. Tablet according to claim 6 or 7, characterised in that the dry binder is microcrystalline cellulose or a mixture of microcrystalline cellulose and a copolymer of vinylpyrrolidone and vinyl acetate.
9. Tablet according to one of claims 1 to 8, characterised in that it contains 0.2 to 80 wt.%, preferably 0.7 to 40 wt.% of a compound of formula I.
@
10. Tablet according to one of claims 1 to 9, characterised in that the weight ratio between the wetting agent and the active substance of formula I is in a range of about 1 : 200 to about 1: 5, preferably between about 1: 150 to about 1 : 10.
11. Tablet according to one of claims 5 to 10, characterised in that the weight ratio between lactose or mannitol and the active substance of formula I is in the range from about 20 : 1 to about 1: 4, preferably about 12 : 1 to about 1: 1.2.
12. Tablet according to one of claims 5 to 11, characterised in that the weight ratio between lactose and the active substance of formula I is in the range from about 4 : 1 to about 1 : 4, preferably about 1.8 : 1 to about 1: 1.2.
13. Tablet according to one of claims 5 to 11, characterised in that the weight ratio between mannitol and the active substance of formula I is in a range of about 20:1 to about 1:2, more preferably in a range of about 15:1 to 3:1.
14. Tablet according to one of claims 6 to 13, characterised in that the amount by weight of the disintegrant based on the total mass of the tablet is in a range from about 0.5 to 10 wt. %.
15. Tablet according to one of claims 5 to 14, characterised in that the amount by weight of the flow agent, lubricant and separating agent based on the total mass of the tablet is in a range from about 0.1 to S wt. % .
16. Tablet according to one of claims 1 to 15, characterised in that it consists essentially of the following ingredients: ° a compound of formula I; eo microcrystalline cellulose;
30 . lactose or mannitol, e optionally a copolymer of vinylpyrrolidone and vinyl acetate; . sodium laurylsulphate;
’ ® -22- e crosslinked polyvinylpyrrolidone or a crosslinked cellulosecarboxymethylether sodium salt, particularly croscarmelliose sodium salt; * magnesium stearate; and e optionally a pharmaceutically acceptable colouring.
17. Process for preparing a tablet according to one of claims 1 to 16 [comprising] (a) mixing a compound of formula I with a wetting agent and optionally other pharmacologically acceptable excipients, optionally in the presence of a volatile diluent; (b) screening the mixture obtained, (c) optionally adding a lubricant , and (d) compressing with a suitable tablet press.
18. Use of a tablet according to one of claims 1 to 16 for preparing a pharmaceutical composition for the treatment or prevention of diseases in which LTB, antagonists can be used therapeutically or preventively.
19. Use of a tablet according to one of claims 1 to 16 for preparing a pharmaceutical composition for the treatment or prevention of arthritis, asthma, chronic obstructive pulmonary diseases, psoriasis, ulcerative colitis, Alzheimer’s disease, shock, reperfusion damage/ischaemia, cystic fibrosis, atherosclerosis and multiple sclerosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10134377 | 2001-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200309710B true ZA200309710B (en) | 2004-06-04 |
Family
ID=7691857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200309710A ZA200309710B (en) | 2001-07-14 | 2003-12-15 | Pharmaceutical formulation containing an LTB4 antagonist. |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR036339A1 (en) |
CO (1) | CO5560535A2 (en) |
DE (2) | DE10206241A1 (en) |
PE (1) | PE20030255A1 (en) |
SA (1) | SA03230511A (en) |
ZA (1) | ZA200309710B (en) |
-
2002
- 2002-02-15 DE DE10206241A patent/DE10206241A1/en not_active Withdrawn
- 2002-07-09 DE DE50203521T patent/DE50203521D1/en not_active Expired - Fee Related
- 2002-07-12 AR ARP020102604A patent/AR036339A1/en not_active Suspension/Interruption
- 2002-07-12 PE PE2002000623A patent/PE20030255A1/en not_active Application Discontinuation
-
2003
- 2003-01-13 SA SA03230511A patent/SA03230511A/en unknown
- 2003-12-15 ZA ZA200309710A patent/ZA200309710B/en unknown
-
2004
- 2004-02-10 CO CO04010954A patent/CO5560535A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE10206241A1 (en) | 2003-01-30 |
AR036339A1 (en) | 2004-09-01 |
PE20030255A1 (en) | 2003-04-22 |
DE50203521D1 (en) | 2005-08-04 |
CO5560535A2 (en) | 2005-09-30 |
SA03230511A (en) | 2005-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1468679B1 (en) | Controlled release formulation containing tramadol | |
KR100728846B1 (en) | High drug load tablet | |
KR100479521B1 (en) | Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates | |
KR101442862B1 (en) | Solid medicinal preparation containing mannitol or lactose | |
KR101647842B1 (en) | Pharmaceutical composition having improved storage stability | |
EP3662899A1 (en) | Apixaban formulations | |
KR20090016611A (en) | Pharmaceutical compositions of memantine | |
PL200163B1 (en) | Delavirdine tablet formulation | |
CH703897B1 (en) | Solid dosage form of olmesartan medoxomil and amlodipine. | |
EP1321142A1 (en) | Solid pharmaceutical composition for oral administration of Tegaserod | |
KR20010086062A (en) | Sustained release matrix systems for highly soluble drugs | |
ZA200309289B (en) | Oxcarbazepine dosage forms. | |
EP2481397A1 (en) | Pharmaceutical compositions comprising tasocitinib | |
US20020132839A1 (en) | Tablet formulations comprising valsartan | |
EP2559431A1 (en) | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide | |
WO2004012722A2 (en) | Bicifadine formulation | |
JP2023052494A (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
AU2002333235B2 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
US20030022928A1 (en) | Novel compositions of eprosartan | |
US20100003319A1 (en) | Raloxifene immediate release tablets | |
US20030119901A1 (en) | Pharmaceutical formulation containing an LTB4 antagonist | |
ZA200309710B (en) | Pharmaceutical formulation containing an LTB4 antagonist. | |
RU2674978C2 (en) | Pharmaceutical composition of n-[5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide | |
US10548848B2 (en) | Alogliptin formulation | |
US20020160048A1 (en) | Medical formulation containing a muscarinic agonist |